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Efforts to develop a vaccine against HIV have so far
met with limited success. Given that CD4+ T cell acti-
vation drives the initial burst of viral replication, we
explored in macaques whether an oral vaccine
comprised of Lactobacillus plantarum, a commensal
bacterium that favors immune tolerance, and
inactivated simian immunodeficiency virus mac239
(SIVmac239) would induce CD4+ T cell unresponsive-
ness/tolerance toward SIV antigens and thereby
prevent the establishment of SIV infection. The
tolerogenic vaccine induced MHC-Ib/E-restricted
CD8+ regulatory T cells (Tregs) that suppressed SIV-
harboring CD4+ T cell activation and ex vivo SIV repli-
cation in 15 of 16 animals without inducing SIV-
specific antibodies or cytotoxic T lymphocytes. Of
16 macaques that were intrarectally challenged with
SIVmac239 or heterologous strain SIVB670, 15 were
sterilely protected. In four macaques that were re-
challenged intravenously, plasma SIV levels peaked
slightly and then dropped to undetectable levels,
although theanimals subsequently harbored intracel-
lular SIV DNA. Infusion of CD8 antibodies confirmed
the role of CD8+ Tregs in preventing/suppressing
SIV in vivo. These findings suggest a new avenue of
research toward developing an HIV-1 vaccine.INTRODUCTION
Efficient vaccines against viral infections generally elicit virus-
specific neutralizing antibodies and sometimes also cytotoxic T
lymphocytes (CTLs) that prevent virus infection and/or eradicate
the virus rapidly after it enters the body (Plotkin, 2010). So far,
however, this process does not seem to work for HIV type 1
(HIV-1) infection, as shown by the failure to generate efficient
long-lasting HIV-specific immunity via either neutralizing anti-
bodies or CTLs induced by the vaccine prototypes that have
been tested over the last 20 years (Fauci et al., 2008). Recently,1736 Cell Reports 2, 1736–1746, December 27, 2012 ª2012 The Autthe ALVAC-AIDSVAX vaccine trial showed that vaccinated indi-
viduals had a modest and short-term decreased incidence of
HIV-1 acquisition (Rerks-Ngarm et al., 2009). However, more dis-
turbing are the results of the STEP study, which showed an initial
increase in virus acquisition in the group of vaccinated individ-
uals compared with the placebo group (Buchbinder et al.,
2008; Duerr et al., 2012). It is known that CD4+ T cell activation
drives the initial burst of viral replication that leads to virus
dissemination in vivo (Andrieu and Lu, 1995; Fauci, 1996). There-
fore, the enhanced risk of infection observed in the STEP study
could potentially be explained by the fact that the vaccine gener-
atedHIV-1-specific CD4+ T cells that on one handmay helpCTLs
to eradicate the virus, and on the other hand provide a substrate
for efficient HIV-1 replication (Douek et al., 2002). Indeed, it has
previously been shown that mucosal SIV transmission could be
prevented in macaques by the local administration of an anti-
inflammatory agent that prevented immune activation (Li et al.,
2009). Against this background, we propose here that induction
of HIV-1-specific tolerance might prevent the establishment of
HIV-1 infection through suppression of CD4+ T cell activation.
To test this hypothesis, we used themodel of the simian immu-
nodeficiency virus (SIV) in macaques of Chinese origin, which
best mimics HIV-1 infection in humans (Chen et al., 2011; Ling
et al., 2002; Marcondes et al., 2006; Stahl-Hennig et al., 2007).
We assessed whether an oral vaccine that favors immune toler-
ance and consists of Lactobacillus plantarum (LP) (Kleerebezem
et al., 2003), a digestive tract commensal bacterium (Grangette
et al., 2005; van Baarlen et al., 2009), and inactivated SIV would
induce CD4+ T cell unresponsiveness/tolerance toward SIV
antigens, which would in turn inhibit viral replication in vivo.
RESULTS
Induction of SIV-Specific Tolerance by an Oral Vaccine
In the first set of experiments, eight Chinese macaques were
immunized via the intragastric route with aldrithiol-2 (AT-2)/
heat-inactivated SIVmac239 (iSIV) (Rossio et al., 1998) formu-
lated with LP, whereas control animals received LP only (four
macaques) or iSIV only (four macaques). No difference was
observed in the distribution of the classical major histocompati-
bility complex 1 (MHC-1) genotypes of the 16 animals (Table S1).
No side effect was observed after the vaccine was administered.hors
Figure 1. Humoral and Cellular Immune
Responses following Intragastric Immuni-
zation with AT-2/iSIV and LP
(A) Plasma SIV IgM antibody titers.
(B) Plasma SIV IgG antibody titers.
(C) Plasma SIV IgA antibody titers.
(D) Anti-SIV IgA in the rectum washing at 60 days
postimmunization.
(E) SIV (Gag p27, Gag peptides or AT-2 SIV)-
specific proliferation (mean ± SD) of CD4+ and
CD8+ T cells at 60 days postimmunization. See
also Figure S1.
(F) SIV Gag-specific IFN-g-releasing T cells
(mean ± SD) at 60 days postimmunization.
See also Table S1.Because tolerance generally includes antigen-specific unre-
sponsiveness of both the humoral and cellular arms of immunity,
we looked first at SIV antibodies. We were unable to detect SIV-
specific antibodies in the LP/iSIV-immunized monkeys, whereas
we detected low titers of SIV immunoglobulin M (IgM) and IgG
antibodies in the plasma of iSIV-treated controls (Figures 1A
and 1B). Similarly, SIV IgA antibodies were not detected in the
plasma and rectum washings of LP/iSIV-immunized monkeys
or iSIV-treated controls, whereas they were detected in SIV-
infected monkeys (Figures 1C and 1D). Due to the absence of
reagents, SIV secretory-IgA antibodies were not checked. We
then tested for SIV-specific cellular responses. Twomonths after
immunization, SIV Gag-p27- and Gag-peptide-specific CD4+
T cell proliferation was not detected in any of the eight iSIV/LP-
immunized animals, whereas it was present in the four iSIV-
treated controls (p < 0.01). In contrast, SIV Gag-specific
CD8+T cell proliferation was observed in both the eight iSIV/
LP-immunized monkeys and the four iSIV-treated controls
(p > 0.05; Figure 1E and Figure S1). Interferon g (IFN-g)-secreting
T cells (CTLs) were also not detected upon SIV Gag p27 stimula-
tion in the eight iSIV/LP-immunized animals, but were found
(although at a low frequency) in the four iSIV-treated controls
(p < 0.01; Figure 1F). We also depleted CD4+CD25+Foxp3+ regu-
latory T cells (Tregs) from the peripheral bloodmononuclear cellsCell Reports 2, 1736–1746, De(PBMCs) of immunized macaques using
an CD25 monoclonal antibody. This had
no effect on p27-specific T cell unrespon-
siveness in vitro (Figure 1F). Furthermore,
we showed that there was no specific
interleukin 10 (IL-10) or transforming
growth factor b (TGF-b) release upon
stimulation with SIV Gag p27 or Gag
peptides in either the iSIV/LP-immunized
or control animals (data not shown).
Suppression of SIV-Specific CD4+T
Cell Activation by Nonclassical
MHC-Restricted CD8+T Cells
We next investigated whether this form of
immune tolerance involves a suppression
of activation of SIV-positive CD4+ T cells.
Because infected CD4+ T cells presentGag antigen derived from entering virions, i.e., before viral inte-
gration and viral protein expression (Sacha et al., 2007a), we
pulsed fresh PBMCs from iSIV/LP-immunized macaques and
control animals with nonreplicative (AT-2-treated) SIVmac239.
As expected (Vatakis et al., 2009), 5% of the CD4+ T cells of
all of the monkeys were ‘‘infected’’ by AT-2-treated (killed) SIV,
as evidenced by intracellular p27 staining (Figures 2A and 2B).
We then stimulated PBMCs overnight with staphylococcal
enterotoxin B (SEB) and CD3/CD28 antibodies in the presence
or absence (after depletion) of autologous CD8+ T cells and
assayed for p27+CD4+ T cells bearing the early activation/
proliferation marker Ki-67. We found that the percentage of acti-
vated (Ki-67+) p27+CD4+ T cells was much lower in PBMCs from
iSIV/LP-immunized macaques than in PBMCs from LP- or iSIV-
treated animals (mean ± SD, 8.9% ± 2.7% versus 49.1% ± 9.1%
or 53.4% ± 7.0%, p < 0.01). Moreover, in PBMCs from iSIV/LP-
immunized macaques, the percentage of Ki-67+p27+CD4+
T cells was also much lower in the presence than in the absence
of autologous CD8+ T cells (mean ± SD, 8.9% ± 2.7% versus
54.5% ± 6.3%, p < 0.01). By contrast, in PBMCs from LP- or
iSIV-treated animals, the percentages of Ki-67+p27+CD4+
T cells remained high in either the presence or absence of
autologous CD8+ T cells (49.1% ± 9.1% and 53.4% ± 7.0%,
respectively, p > 0.05; or 52.9% ± 7.4% and 57.5% ± 8.4%,cember 27, 2012 ª2012 The Authors 1737
Figure 2. Suppression of SIV-Specific CD4+
T Cell Activation by Nonclassical MHC-
Restricted CD8+ T Cells at 60 Days following
Intragastric Immunization with iSIV and LP
(A) SIV Gag p27 (green) in the cytoplasm (red) of
nonreplicative (AT-2-treated) SIV-pulsed quies-
cent CD4+T cells visualized by fluorescent con-
focal microscopy.
(B) SIV Gag p27+ cells in nonreplicative SIV-pulsed
quiescent CD4+ T cells following 16 and 48 hr
poststimulation analyzed by flow cytometry (SIV-
pulsed cells in green and nonpulsed cells in violet).
(C) Representative data for the activation marker
Ki67 and SIV Gag p27+ cells within gated CD4+
T cells in nonreplicative SIV-pulsed PBMCs
(depleted or not of CD8+T cells) at 48 hr post-
stimulation by flow cytometry.
(D) Expression (mean ± SD) of Ki-67 within SIV
Gag p27+ cells on the gated CD4+ T cells in AT-2
SIV-pulsed PBMCs (depleted or not of CD8+ or
CD25+T cells) taken from iSIV/LP-immunized
animals and iSIV or LP-treated animals.
(E) Expression of Ki-67 within SIV Gag p27+ (AT-2
SIV-pulsed) CD4+ T cells in the presence of
autologous or allogenic CD8+T cells.
(F) Cytotoxicity (mean ± SD) of AT-2 SIV-pulsed
CD4+ T cells in the presence of CD8+ T cells or of
K562 in the presence of human natural killer cells
(controls) with or without SEB and anti-CD3/CD28
stimulation.respectively, p > 0.05; Figures 2C and 2D). We also showed that
iSIV/LP-induced CD8+ T cells operated through a nonclassical
MHC-restricted mechanism, because they suppressed the acti-
vation of nonreplicative SIV-pulsed CD4+ T cells from other iSIV/
LP-immunized monkeys as well as those from control animals
(p > 0.05; Figure 2E). Moreover, because the depletion of
CD25+ cells did not modify the suppressive activity of PBMCs
on p27+CD4+T cell activation (Figure 2D), we concluded that
Tregs had no role in this suppression process. Finally, we
controlled for the absence of CD4+ T cell lysis (p > 0.05) using
a highly sensitive cytotoxicity assay (Marchetti et al., 1996; Fig-
ure 2F). Together, these results support the conclusion that
a noncytotoxic mechanism underlies the CD8+ T cell-mediated
suppression.
Suppression of Virus Replication by MHC-Ib/E
Restricted CD8+ T Cells
Having demonstrated that adding LP to iSIV turned a classical
SIV-specific immune response into an SIV-specific, CD8+
T-dependent tolerance, including the suppression of SIV-posi-
tive CD4+ T cell activation, we further studied whether the SIV-
specific CD8+ T cells would suppress the replication of SIV in1738 Cell Reports 2, 1736–1746, December 27, 2012 ª2012 The Authorsfreshly infected CD4+ T cells ex vivo. We
purified CD8+ T cells from PBMCs from
the iSIV/LP-immunized macaques and
added them to autologous CD4+ T cells
acutely infected with SIVmac239. They
were then stimulated overnight with SEB
and CD3/CD28 antibodies. Over a periodof 5 days, the CD8+ T cells conferred a strong antiviral activity in
the coculture (p < 0.001) (Figure 3A). If the CD8+T cells were
added more than 48 hr poststimulation (i.e., at a time when SIV-
specific CD4+ T cell activation was well established), they could
no longer inhibit viral replication (p < 0.001) (Figure 3B). This
strongly suggests that the antiviral effect of the CD8+ T cells
was generated by suppression of SIV-specificCD4+ T cell activa-
tion. We also demonstrated that the CD8+ T cell-mediated anti-
viral activity required cell-to-cell contact (p < 0.001) (Figure 3C)
and was a classical MHC-unrestricted activity (as was the case
for suppression of CD4+ T cell activation), as shown by the strong
inhibition of viral replication by CD8+ T cells on acutely infected
CD4+ T cells from other immunized animals in the group or from
control animals (p < 0.001) (Figure 3D).
Finally, we showed that the CD8+ T cell-mediated antiviral
activity was blocked by an MHC-Ib/E antibody but not by an
ia/ABC antibody, indicating a nonclassical MHC-Ib/E-restricted
CD8+T cell activity (p < 0.001) (Figure 3E). Clearly, T cell receptor
(TCR) expression by CD8+ T cells is essential for recognition
of MHC-Ib/E-peptide complexes carried by target CD4+ T cells
(Sarantopoulos et al., 2004; Van Kaer, 2010). By depleting cell
subsets in vitro with antibody-conjugated magnetic microbeads,
Figure 3. In Vitro Antiviral Activity of CD8+T
Cells following Intragastric Immunization
with iSIV and LP
(A) Anti-SIV activity (fold of viral suppression) of
CD8+ T cells.
(B–F) Anti-SIV activity of CD8+ T cells after 60 days
following oral immunization in a delayed (B), insert
(C), or allogenic (D) culture system, in the presence
of MHC-Ia/ABC or MHC-Ib/E antibodies (E),
and in CD8+ T cells depleted of TCRgd+ or Vb8+
subset (F).
See also Figure S2 and Table S2.we showed that TCRgd and Vb8 were not involved in suppres-
sion of viral replication (p > 0.05) (Figure 3F), suggesting that
TCRab plays a central role in the recognition of MHC-Ib/E-
peptide on infected CD4+T cells. However, even though we
tested for a large number of CD8+T-cell-associated CD antigens
(by depleting CD8+ T cells with human antibodies cross-reacting
with membrane CD antigens of nonhuman primates), we were
not able to identify any CD antigen associated with MHC-Ib/E-
restricted CD8+ T cell activity (p > 0.05) (Table S2). Finally, in
an additional experiment, we found lower peripheral blood
myeloid dendritic cell (mDC) and plasmacytoid DC (pDC) counts
in protected (iSIV/LP-immunized) animals as compared with
infected control animals (p < 0.01 and < 0.05 for mDC and
pDC, respectively) or naive animals (p < 0.001 for both mDC
and pDC) (Figure S2).
Protection of Macaques from Homologous and
Heterologous SIV Challenges
Having established that oral immunization with iSIV/LP induced
an SIV-specific tolerance that suppressed viral replication
ex vivo, and that both suppression of CD4+ T cell activation and
inhibition of viral replication resulted from the activity of non-
IFN-g-secreting TCRab MHC-Ib/E-restricted CD8+ T cells, we
sought to determine whether such a tolerogenic vaccine would
protect macaques from mucosal SIV infection. To that end, weCell Reports 2, 1736–1746, Dechallenged the eight iSIV/LP-immunized
and eight control animals intrarectally
with a high dose (100,000 TCID50) of SIV-
mac239 3 months after immunization
(Chen et al., 2011). Surprisingly, the eight
immunized animals were fully protected
without any detectable level of plasma
SIV RNA or PBMC proviral DNA. By
contrast, the eight control animals were
all infected (p < 0.001) (Figure 4A).
We further wanted to observe whether
the animals that were protected against
intrarectal SIV challenge could also be
protected against an intravenous chal-
lenge. Two months after the intrarectal
challenge, four out of the eight monkeys
were challenged via the intravenous route
with 200 TCID50 of virus. All showed
a slight peak of SIV replication (%200
DNA copies/million PBMCs and 200 SIVcopies/ml of plasma) at day 10 postchallenge. However, by
day 30, plasma SIV RNA had become undetectable (%10
copies/ml) and PBMC SIV DNA had decreased to%10 copies/
million cells, showing the absence of virus replication in vivo. In
contrast, two naive animals that received the same intravenous
SIVmac239 challenge were fully infected (p < 0.001) (Figure 4B).
The four remaining monkeys were intrarectally rechallenged
(100,000 TCID50) and, as expected, remained fully protected
(p < 0.001) (Figure 4C).
To test whether vaccinated monkeys would also be protected
from a heterologous challenge, 8 months later we further chal-
lenged the four intrarectally rechallenged monkeys and the four
intravenously rechallenged monkeys with 100,000 TCID50 of
the antigenically distinct SIVB670 via the intrarectal route. The
eight animals remained fully protected, as shown by their unde-
tectable SIV B670 DNA and RNA levels, whereas two control
naive animals were infected by the same SIV B670 challenge
(p < 0.001). This demonstrated that the SIV-specific tolerogenic
vaccine was cross-protective, presumably through preventing
the activation of CD4+ T cells that were infected by another SIV
strain (Figure 4D).
Longevity of Vaccine-Induced Protection
We further immunized a new group of 16 macaques (eight with
iSIV/LP, four with iSIV, and four with LP) (Table S3) to study thecember 27, 2012 ª2012 The Authors 1739
Figure 4. Prevention of SIV Infection in iSIV/
LP-Immunized Macaques Challenged with
Different Pathogenic SIV Strains
(A–D) Plasma and PBMC viral loads of rhesus
macaques intragastrically immunized with iSIV
and LP after (A) a first challenge performed intra-
rectally with SIVmac239 (100,000 TCID50) in eight
macaques and in eight control monkeys treated
with LP alone or iSIV alone, (B) a second SIV-
mac239 challenge performed intravenously (200
TCID50) in four immunized monkeys and two naive
monkeys, (C) a second SIVmac239 challenge
performed by intrarectal route in the four remaining
immunized monkeys and two naive monkeys, and
(D) a third intrarectal challenge performed intra-
rectally with SIVB670 in the eight immunized
macaques and two additional naive monkeys.longevity of the protection. The ex vivo antiviral activity of cells
from this group was followed regularly. We observed that seven
of the eight animals that received iSIV/LP maintained a high
ex vivo antiviral activity of R100-fold compared with controls
for up to 420 days (p < 0.001) (Figure 5A). As expected, no
antiviral activity was detected in cells from animals treated with
iSIV or LP alone.
On day 420 postimmunization, all 16 animals were intrarectally
challenged with 100,000 TCID50 of SIVmac239. Seven out of the
eight iSIV/LP-immunized animals had a sterile immunity as indi-
cated by the absence of any SIV RNA and DNA emergence in
plasma, PBMCs (Figures 5B and 5C), rectal mucosa lympho-
cytes (measured from day 1 postchallenge), or pelvic lymph no-
des (Figure S3). Interestingly, one iSIV/LP-immunized macaque1740 Cell Reports 2, 1736–1746, December 27, 2012 ª2012 The Authorsas well as all four of the iSIV-treated and
all four of the LP-treated monkeys
became fully infected (p < 0.001; Figures
5B and 5C; Figure S3). Moreover, the
evolution of the ex vivo antiviral activity
of the eight vaccinated monkeys allowed
us to predict, from day 360 postimmuni-
zation (i.e., 60 days before their chal-
lenge), which one of the eight immunized
monkeys would not be protected (Figures
5A and 5B).
Role of CD8+ T Cells in Suppressing
SIV Replication In Vivo
In order to confirm the role of CD8+ T cells
in vivo, we temporarily depleted CD8+
T cells from peripheral blood and
lymphoid organs in the eight already chal-
lenged and protected monkeys in the first
group of animals. Three intravenous
injections of a mouse-human chimeric
monoclonal CD8 antibody, cMT-807
(Centocor), were administered over a
period of 1 week at days 300, 304, and
307 postimmunization (Figure 6A), and
viral RNA and DNA were monitored. Inthe four macaques that had been rechallenged by the intrarectal
route, no viral RNA or DNA was detected, demonstrating again
their sterile protection. Interestingly and by contrast, a strong
viral replication was observed in the four animals that had previ-
ously been challenged intravenously and harbored proviral
DNA. In these animals, at the nadir of CD8+ T cell depletion
(day 15), virus replication peaked at 106 RNA copies/ml of
plasma, and lymph node proviral loads reached 104 DNA
copies/106 cells (p < 0.001). However, by days 60–90, as the
four animals recovered baseline CD8+T cell concentrations,
virus replication was again brought under control, as indicated
by plasma SIV RNA and PBMCs and lymph node SIV DNA re-
turning to baseline levels (p > 0.05) (Figures 6B and 6C). This
confirmed the unique role of the vaccine-induced CD8+ T cells
Figure 5. In Vitro and In Vivo CD8+Treg-Mediated Antiviral Activity
after Intragastric Immunizationwith iSIV and LP in a Second Set of 16
Macaques
(A) Anti-SIV activity (fold of viral suppression) of CD8+ T cells during 60–
420 days postimmunization.
(B) Plasma viral loads >90 days after intrarectal challenge.
(C) Cellular SIV DNA loads >90 days after intrarectal challenge.
See also Figure S3 and Table S3.
Figure 6. Depletion of Peripheral Blood and Lymph Node CD8+T
Cells in Eight iSIV/LP-Treated Macaques by Infusion of the CD8
Antibody cMT807
(A) Peripheral bloodCD8+ T cell counts and lymph nodeCD8+T cell percentage
(%) before and after three injections of cMT807.
(B) Plasma and cellular viral loads before and after three injections of cMT807
in the eight iSIV/LP-immunizedmonkeys. Fourmacaques (iSIV/LP #1–4, in red)
were previously intravenously challenged and four (iSIV/LP #5–8, in green)
were previously intrarectally challenged.
(C) Lymph node SIV DNA loads before and after three injections of cMT807.
Four macaques (iSIV/LP #1–4, in violet) were previously intravenously chal-
lenged and four (iSIV/LP #5–8, in green) were previously intrarectally chal-
lenged.in controlling viral replication in intravenously SIV-challenged
animals in which replication-competent virus remained latent,
presumably in quiescent memory CD4+ T cells (Willerford
et al., 1990). A similar state of latency has been observed in
HIV-1 patients treated with highly active antiviral therapy (Finzi
et al., 1997).
Role of CD8+ T Cells in Protecting Macaques against
Intrarectal SIV Challenge
To further define the role of CD8+ T cells in protecting against
mucosal (rectal) challenge, we redepleted CD8+ T cells in the
four macaques (#5–8) that previously had been sterilely pro-
tected through three intrarectal challenges (performed 3, 5
and 13 months postimmunization). The CD8 antibody (cMT-
807) was administered 36 months postimmunization overCell Rea period of 1 week (days 0, 4, and 7) to temporarily deplete
the CD8+ T cells in the same manner as described above.
However, in this set of experiments, 2 hr after the first adminis-
tration of CD8 antibody, the four monkeys were challenged
intrarectally with 100,000 TCID50 of SIV239. As before, the
cMT-807 treatment dramatically reduced the percentage of
CD8+ T cells in PBMCs (Figure 7A). Consistent with our previous
observations regarding the role of CD8+ T cells, all of the
animals became infected. Indeed, at the nadir of the CD8+T
cell count, the plasma viral loads of the four animals peaked
at 104106 RNA copies/ml (Figure 7B) and 103104 copies
of SIV DNA per million PBMCs (Figure 7C). By weeks 4–7,
when the CD8+ T cell concentrations in the four monkeys
had recovered to almost normal levels, plasma SIV RNA drop-
ped to almost undetectable levels (10–50 copies/ml). Thisports 2, 1736–1746, December 27, 2012 ª2012 The Authors 1741
Figure 7. Intrarectal Challenge of SIVmac239 in Four iSIV/LP-
Immunized and Protected Macaques after Infusion with the CD8
Antibody cMT807
(A) Peripheral blood CD8+T cell counts (%) before and after three injections
of cMT807.
(B) Plasma SIV RNA loads before and after three injections of cMT807.
(C) SIV DNA loads in PBMCs before and after three injections of cMT807.experiment further demonstrated the central role of CD8+ T cells
in preventing initial infection at the mucosal barrier in immunized
animals. When the CD8+ T cells were depleted, the virus repli-
cated freely in lymphoid organs, but as soon as the vaccine-
induced CD8+ T cells recovered, they again strongly controlled
viral replication. Consistent with the above observations
regarding intravenous challenge, the recovered animals now
contained SIV DNA in target cells (Figure 7C), but without
obvious viral replication (Figure 7B).1742 Cell Reports 2, 1736–1746, December 27, 2012 ª2012 The AutDISCUSSION
In the SIV-macaque model, we have demonstrated that infection
can be prevented by inducing immunological tolerance against
the infecting agent. The administration of iSIVmac239 and LP,
a nonpathogenic commensal bacterium of the digestive tract
that is known to induce immunologic tolerance, stimulated the
macaques to develop a thus far unrecognized type of SIV-
specific tolerance. This tolerance was characterized by the
suppression of SIV-specific antibody and CTL responses, and
activation of a subset of CD8+ T cells that are SIV-specific, non-
cytolytic, and MHC-Ib/E restricted. These cells apparently have
the ability to suppress CD4+ T cells activated by SIV and thereby
prevent the establishment of productive SIV infection both in vivo
and in vitro.
These suppressive noncytolytic MHC-Ib/E-restricted CD8+
T cells represent a class of CD8+ Tregs that has not been
described previously in the context of any vaccination or in SIV
or HIV infection. Thus far, the only Tregs that have been
proposed to be associated with HIV infection are CD4+ Tregs
(CD25+FoxP3+CD4+ T cells) that are known to be involved in
some models of immune tolerance (Faria and Weiner, 2005);
however, their role in HIV infection is not clearly understood.
On the one hand, the expansion of CD4+ Tregs has been shown
to be associatedwith the suppression of HIV-specific CD4+ T cell
responses and disease progression (Aandahl et al., 2004;
Nilsson et al., 2006; Weiss et al., 2004), whereas on the other
hand, CD4+ Tregs have been associated with protection from
productive infection, CD4+T cell activation, and disease progres-
sion in both humans (Card et al., 2009; Chase et al., 2008;
Legrand et al., 2006) and nonhuman primates (Jacquelin et al.,
2009; Kornfeld et al., 2005). In the study presented here, the
ex vivo removal of CD25+FoxP3+CD4+ T cells by a CD25 anti-
body did not modify either the suppression of CD4+T cell activa-
tion or viral replication.
Except for the fact that they are noncytolytic, the CD8+ Tregs
observed here resemble those that target and eliminate abnor-
mally activated antigen-specific CD4+ T helper cells in themouse
model (Kim et al., 2010; Sarantopoulos et al., 2004), where the
inhibitory interaction depends on recognition of surface Qa-1
(corresponding to MHC-Ib/E in macaques and to HLA-E in
humans) expressed by aberrantly activated target cells (Kim
et al., 2011; Nagarajan et al., 2012). Similar CD8+ Tregs have
also been implicated in the control of autoimmune type 1
diabetes in humans (Jiang et al., 2010).
Because monkeys challenged via the intrarectal route were
negative for both SIV RNA in plasma and SIV DNA in PBMCs,
our results suggest that virus infection was arrested before
nuclear integration occurred. In quiescent CD4+ T cells, virus
penetration is followed within 2 hr by the presentation at the
plasma membrane of Gag/Pol and other protein epitopes
derived from incoming virions (Sacha et al., 2007a), whereas
Env and Nef proteins need de novo synthesis (Sacha et al.,
2007b). The subsequent phases of the infectious process,
including reverse transcription and proviral DNA integration,
develop inefficiently in quiescent CD4+ T cells but very effi-
ciently in activated CD4+ T cells (Korin and Zack, 1999; Zack
et al., 1990). This is in keeping with the notion that the earlyhors
activation of a small founder population of infected CD4+
T cells at the portal of entry is required for the local expansion
and establishment of systemic infection (Haase, 2011; Zhang
et al., 2004). This early event potentially provides vaccine-
induced CD8+ T cells the opportunity to arrest the infectious
process before proviral DNA integration occurs. We observed
that the withdrawal of vaccine-induced CD8+ T cells from
PBMC cultures before CD4+ T cell activation allowed the
CD4+ T cells to become activated and viral replication to pro-
ceed. Similarly, in vivo depletion of CD8+ T cells performed at
the time of intrarectal challenge allowed the CD4+ T cells to
be activated and the virus to replicate. Such replication,
however, was brought under control as the CD8+ T cells recov-
ered in lymphoid organs and the blood stream. We showed in
cultures ex vivo that the inhibition of viral replication was
directly attributable to this class of CD8+ Tregs. This is highly
likely to be the case in vivo as well; however, direct evi-
dence is lacking because we were restricted to depletion of
the whole CD8+ T cell population rather than the Treg subset
specifically.
So far, we have not identified any CD antigen specifically
associated with the vaccine-induced CD8+ Tregs observed in
this study. The phenotypic and molecular characteristics of
these CD8+ Tregs therefore require further study. Further
studies are also necessary to elucidate how peripheral DCs
are downregulated in vaccinated monkeys, because pre-
vious publications have reported that DC expansion is downre-
gulated in vivo by classical Tregs (Kim et al., 2007; Liu et al.,
2009).
In intravenously challenged monkeys, the transient peak of
viral replication followed by the residual presence of cellular
SIV DNA at a low level suggested that infectious SIV particles
that entered the body by this route encountered activated
CD4+ T cells, probably in secondary lymphoid organs, that
allowed the virus to complete the first cycles of replication. We
assume, however, that any newly released virions then entered
nonactivated (quiescent) CD4+ T cells that were prevented
from becoming activated by the LP/iSIV-generated CD8+
Tregs. Given that in vitro, SIV antigen-specific CD8+ Tregs of
immunizedmacaques were effective enough to inhibit the super-
antigen SEB and CD3/CD28 antibody activation of infected
CD4+ T cells (Figures 2C–2E), it is likely that in vivo, the activation
of SIV-infected CD4+ T cells by SIV-unrelated stimuli known to
upregulate viral replication (Andrieu and Lu, 1995; Fauci, 1996)
will also be inhibited.
The protective effect of this innovative immunization regimen
against SIV challenge, together with the identification of a corre-
late of protection in vitro, is quite striking. Given that SIV and HIV
require activated immune cells in which to replicate, this tolero-
genic vaccine approach may offer an exciting new avenue in
HIV vaccine research. Moreover, the de novo induction of this
class of CD8+ Tregs could potentially be used therapeutically
to suppress HIV replication and prevent disease progression
in place of antiviral therapy. Furthermore, the tolerogenic
vaccine approach described here could potentially be exploited
in the management of a wide range of immune disorders and
is likely to have profound implications across immunology
generally.Cell ReEXPERIMENTAL PROCEDURES
Animals
Colony-bred rhesus macaques (Macaca mulatta) of Chinese origin were
housed at the Nonhuman Primate Laboratory of the Gaoyao Experimental
Animal Center (Guangdong, PRC) in accordance with the National Institutes
of Health’s ‘‘Guide for the Care and Use of Laboratory Animals.’’ All animals
were in good health, 2–4 years old, and weighed 4–6 kg, and were seronega-
tive for SIV, simian retrovirus, simian T cell lymphotropic virus 1, hepatitis
B virus, and herpesvirus simiae (B virus).
Viral Preparation
SIV was produced in CEM174 cells inoculated with SIVmac239 (gift of
P.A. Marx; Chen et al., 2011). The culture supernatants were collected at
peak virus production and inactivated first with 250 mM AT-2 (Sigma-Aldrich,
St. Louis) (Rossio et al., 1998) and then by heating at 56C for 30 min. The
inactivated virus was inoculated to CEM174 cells to verify the 100% inhibition
of viral infectivity.
Bacterial Preparation
LP (ATCC8014) was cultured at 37C in MRS medium with a rotation rate of
200 rpm. To obtain LP at the logarithmic (midlog) phase of bacterial culture,
bacteria were cultured until they reached an optical density at 600 nm of 1.0
with a final LP concentration of1010 cfu/ml (3.5 hr) (van Baarlen et al., 2009).
Oral Delivery of the Vaccine
In the first study, 16monkeys that had fasted overnight were anesthetized with
intramuscular tiletamine hydrochloride and zolazepam (0.7 mg/kg). Eight
animals (iSIV/LP #1–8) were then intragastrically administered 30 ml of a prep-
aration containing 4 3 107 copies/ml of iSIV and 3 3 109 cfu/ml of living LP in
maltodextrin (20%) solution. Monkeys received 25 ml of the same preparation
intragastrically every 30 min for 3 hr. The same protocol was performed over
five consecutive days. Four control animals (LP #1–4) received living LP alone,
and the remaining four (iSIV #1–4) received only iSIV according to the same
protocol.
In the second study, 16 new animals were recruited on the same screening
basis: eight animals (iSIV/LP #9–16) received the same dose of the same
vaccine, four (LP #5–8) were administered living LP alone, and four (iSIV
#5–8) received only iSIV.
Assay for Antibody Responses to SIV
Plasma SIV IgG, IgM, and IgA antibodies were titrated by an immunofluores-
cence antibody assay (IFA) (Tsai et al., 1993) using fluorescein isothiocyanate
(FITC)-conjugated goal anti-macaque IgG (Sigma), IgM (ADI, San Antonio, TX,
USA), or IgA (ADI) antibodies. The sensitivity of the IFA assay was a titer of 20
for IgG and a titer of 5 for IgM and IgA. When a plasma sample was below the
assay sensitivity, a value of one was assigned. Mucosal secretions were
collected by washing the rectum with PBS using a catheter for gastric instilla-
tion as described previously (Me´derle´ et al., 2003). Anti-SIV IgA titers in the
rectum were measured by the IFA assay.
Flow Cytometry
Flow-cytometry analysis was carried out with FACScalibur (BD Biosciences,
San Jose, CA, USA) using the following fluorescence-labeledmonoclonal anti-
bodies: CD3-FITC (clone SP34-2), CD3-PE-Cy7, CD4-PE or CD4-PerCP-Cy5
(clone MT477), CD8-PerCP (clone RPA-T8), and Ki67-PE (BD Biosciences).
FITC-conjugated P27 monoclonal antibody (Fitzgerald, Concord, MA, USA)
or biotin-conjugated P27 monoclonal antibody (Fitzgerald) coupled with
APC-SAv (BD Biosciences) was used for the intracellular staining of SIV-
infected cells. Phycoerythrin (PE)-conjugated monoclonal antibodies against
TCRgd (clone B1), Vb8, and CD antigens CD7, CD16, CD28, CD62L, CD95,
CD122, CD137, CD150, CD183, CD184, CD195, CD196, CD197, CD226,
CD272, and CD305 were purchased from BD Biosciences; PE-conjugated
monoclonal antibodies against CD antigens CD11a, CD25, CD27, CD39,
CD101, CD129, CD215, CD277, and CD357 were purchased from BioLegend
(San Diego, CA, USA); and PE-conjugated monoclonal antibodies against CDports 2, 1736–1746, December 27, 2012 ª2012 The Authors 1743
antigens CD127, CD247, and CD279 were purchased from eBioscience
(San Diego, CA, USA).
SIV-Specific Cell Proliferation Assay
PBMCs were obtained from fresh blood by centrifugation through Ficoll-
Hypaque (Sigma). The proliferation of SIV-specific CD4+ or CD8+ T cells was
evaluated by flow cytometry using the carboxy-fluorescein diacetate, succini-
midyl ester (CFSE) labeling assay (Molecular Probes, Eugene, OR, USA).
CFSE-labeled cells were stimulated for 5 days with 10 mg/ml recombinant
SIV core protein P27 (ImmunoDiagnostics, Woburn, MA, USA), 2 mg/ml SIV
Gag 15-mer peptides (GLS, Shanghai, PRC), 109/ml AT-2-inactivated SIV, or
medium alone.
SIV-Specific ELISpot Assay
IFN-g and IL-10 ELISpot assays were carried out in uncultured PBMCs in the
presence or absence of SIV P27 using a commercial kit (Cell Sciences, Canton,
MA, USA). A TGF-b1 ELISpot kit was purchased from R&D Systems
(Minneapolis). The data were read with an automated ELISpot reader (AID,
GmbH, Strabberg, Germany). The number of SIV P27-specific spot-forming
cells (SFCs) was calculated by subtracting the nonspecific SPCs in the
presence of medium alone.
T Cell Suppression Assay
Fresh PBMCs, depleted (or not) with either CD8 or CD25 by magnetic-bead-
conjugated CD8 or CD25 antibodies (Miltenyi Biotec, Auburn, CA, USA),
were pulsed with nonreplicative (AT-2-treated) SIVmac239 (at a viral concen-
tration of 1010/ml) for 2 hr at 37C in a 5% CO2 incubator. Pulsed cells were
treated overnight with SEB (2.5 mg/ml; Sigma) and CD3 (2.5 mg/ml)/CD28
(2.5 mg/ml) antibodies (BD Biosciences) in RPMI 1640 culture medium (Sigma)
supplemented with 1% fetal calf serum (Sigma) and 2% BSA (Sigma). Simul-
taneous intracellular stainings of SIV P27 and Ki-67 were performed 48 hr after
the nonreplicative SIV pulse in order to determine the percentage of T cell
activation (Ki-67+) within infected (P27+) cell populations. The P27+ cells
were visualized with a fluorescent confocal microscope (Leica TCS SP2; Leica
Microsystems CMS GmbH, Mannheim, Germany) using FITC-conjugated P27
antibody (Fitzgerald) with cytoplasmic staining by Evans Blue (Sigma).
T Cell Cytotoxicity Assay
Both purified CD8+ T cells (effector cells) and purified CD4+T cells pulsed
with 1010 AT-2-treated SIVmac239 (target cells) were labeled with 40 nM
3,30dihexyloxacarbocyanine (DiOC6) (Marchetti et al., 1996) (Molecular
Probes) for 10 min at 37C. Target cells were labeled with PerCP-Cy5-conju-
gated anti-CD4 (BD Bioscience) for 20 min on ice. Effector cells were washed
three times and then mixed with target cells in a U-bottomed, 96-well plate at
different effector/target ratios (3:1, 1:1, and 0.3:1) in triplicate. K562 cells
(target) with APC-conjugated anti-CD32 (BD Bioscience) and purified CD56+
(NK) cells (effector) from four healthy donors were included as an assay
control. After 4 hr of incubation at 37C in the presence of SEB and anti-
CD3/anti-CD28, cells were harvested and analyzed by flow cytometry. Percent
cytotoxicity was calculated as follows: 100 3 (% of total apoptotic target
cells – % of spontaneous apoptotic target cells)/(100 – % of spontaneous
apoptotic target cells).
SIV Suppression Assay
Autologous CD4+ T cells from each animal were purified by magnetic positive
labeling (MicroBeads; Miltenyi Biotec) and then acutely infected with SIV-
mac239 (103 multiplicity of infection) in the presence or absence of magnet-
ically purified CD8+ T cells at a CD4/CD8 ratio of 1:3, and then stimulated with
SEB andCD3/CD28 antibodies for 16 hr. After washing, the cells were cultured
in quadruplicates in 96-well plates. Cultures were maintained in a final volume
of 200 ml per well of RPMI 1640 medium containing 100 IU of human rIL2
(Roche Diagnostics GmbH, Mannheim, Germany) for 5 days. Viral loads
were measured by a real-time RT-PCR in culture supernatants collected at
day 5 (see below). Fold suppression was determined as the geometric means
of viral concentration in the culture supernatants from the infected CD4+ target
cells only divided by the geometric means of viral concentration in the super-
natants from the mixed CD8+ and CD4+ T cells.1744 Cell Reports 2, 1736–1746, December 27, 2012 ª2012 The AutIn some experiments, CD8+ and CD4+ T cells were cultured without cell-to-
cell contact bymeans of aMultiwell Insert System (BDBiosciences; CD8 in the
insert well and CD4 in the bottom well), CD4+ T cells were cocultured with allo-
genic CD8+ T cells in order to determine the correlation between viral suppres-
sion and MHC restriction, and CD8+ and CD4+ T cells were also cocultured in
the presence of MHC-ABC (BioLegend) or MHC-E (Cell Science) antibodies to
define the modes of MHC restriction. To define the subsets of CD8+ T cells
associatedwith antiviral activity,CD8+ Tcellswere purified fromPBMCs imme-
diately after their depletion with PE-conjugate TCRgb, Vb8, or other CD antigen
antibodies using anti-PE microbeads through an LD column (Miltenyi Biotec).
Viral Challenges
Three months after oral administration of the vaccine or the controls, the 16
animals of the first study were inoculated intrarectally with 2,500 MID100
(100,000 TCID50) of pathogenic SIVmac239. Twomonths later, four vaccinated
monkeys were rechallenged via the intrarectal route (100,000 TCID50) and four
others were intravenously rechallenged with 5 MID100 (200 TCID50) of SIV-
mac239. As controls, twomonkeys received an intrarectal challenge and other
two received an intravenous challenge. These infectious doses generally result
in a systemic infection in 100% of Chinese rhesus macaques with a peak
plasma viral load (107109 vp/ml) by days 10–14.
Thirteen months after the intragastric immunization (i.e., 8 months after the
second challenge), the eight animals received a third intrarectal challenge with
100,000 TCID50 of pathogenic SIVB670 (a distinct strain of SIV provided by
F. Villinger, Emory University School of Medicine, Atlanta, GA, USA).
SIVB670 was propagated in vitro using primary macaque PBMCs, and the first
passages of the original viral stocks were used for challenge. Again, two addi-
tional untreated macaques (Mac-naive #5–6) received in parallel an intrarectal
challenge of SIVB670 as control.
In the second study, the 16 animals were intrarectally challenged on day 420
postimmunization with 100,000 TCID50 of SIVmac239.
Viral Loads
Cell-associated SIV DNA or plasma/supernatant SIV RNA was quantified by
a quantitative PCR or RT-PCR with primers (sense, 50-GAGGAAAAGAA
ATTTGGAGCAGAA-30; antisense, 50-GCTTGATGGTCTCCCACACAA-30 ) and
probe (50-FAM-AAAGTTGCACCCCCTATGACA TTAATC AGATGTTA-TAM
RA-30) for SIVmac239 and primers (sense, 50-TTGAGCCCTGGGAGGTTCT-30;
antisense, 50-GCCAAGTGCTGGTGAGAGTCT-30) and probe (50-FAM-AACA
CCCAGGCTCTACCTGCTAGTGCTG-TAMRA-30) for SIVB670 using a 7500
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
The sensitivity of the quantitative PCR or RT-PCR was three and ten copies
for the input SIV DNA and RNA samples, respectively.
Depletion of CD8+T Cells In Vivo
Macaques were first anesthetized and then given an intravenous injection of
a chimeric CD8 monoclonal antibody (cMT-807; Centocor Research & Devel-
opment, Malvern, PA, USA) at 5 mg/kg on days 0, 4, and 7 (Schmitz et al.,
1999). Peripheral blood samples (5 ml) were taken from each animal at day
0 and at various time points after antibody injections.
Statistical Analysis
Unpaired data from different groups of animals, and paired data obtained
before and after immunization were compared by using the t, Mann-Whitney,
and Wilcoxon tests, respectively.
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